Amyloid protein intra-membrane segment for treating Alzheimer disease and application thereof

Abstract

The invention relates to an amyloid protein intra-membrane segment for treating Alzheimer disease and an application thereof, in particular to the application of the amyloid protein intra-membrane segment in the preparation of a vaccine medicament for treating Alzheimer disease. The problem of treating Alzheimer disease can be efficiently solved. The technical scheme provided by the invention is to choose an intra-membrane segment (IF-A beta segment), which is called as AIIGLMVGGVVIA for short, from amino acid sequences of amyloid proteins (A beta42) of 42 amino acids. In a use process, after the synthesized IF-A beta and a Freund adjuvant are mixed and injected to an immunized AD (Alzheimer Disease) model mouse, the A beta42 plaques can be efficiently eliminated, the cognitive function of the AD mouse can be improved and the defect of the sub-acute meningitis caused by using A beta42 as an immunogen can be overcome, thereby developing a therapeutic medicament for efficiently treating AD without side effect.

Description

Technical field [0001] The present invention relates to the medical field, in particular to an amyloid membrane intramembrane fragment for treating Alzheimer's disease and its application, in particular to its application in preparing vaccine preparations for treating Alzheimer's disease. Background technique [0002] An important pathological feature of Alzheimer’s disease (AD) is the formation of Aβ plaques in the brain. The accumulation of Aβ in the brain is the trigger point of a series of pathological cascades in the process of AD. The current research strategy for AD is mainly to reduce the accumulation of amyloid-β (Aβ) in the brain from multiple channels. These include inhibiting the metabolism of APP into Aβ, interfering with the aggregation of Aβ, and increasing the clearance of Aβ. In terms of reducing Aβ deposition and improving spatial cognitive function, Aβ vaccines present the most attractive research prospects. The first study report of Aβ vaccine showed that th...

AI Technical Summary

Problems solved by technology

However, in the clinical phase II trial, 6% of the subjects developed symptoms of subacute meningitis, which led to the termination of the clinical trial

Images